New combo may boost stem cell harvest for myeloma transplant

NCT ID NCT06514508

Recruiting now Disease control Sponsor: Guangzhou Gloria Biosciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 22 times

Summary

This study tests whether adding motixafortide to standard G-CSF helps collect more stem cells for a patient's own transplant. About 60 adults with multiple myeloma will receive either the drug combo or a placebo. The goal is to see if the combo leads to enough stem cells in fewer sessions, making the transplant process smoother.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Harbin The First Hospital
NOT_YET_RECRUITING

Harbin, Hei Longjiang, 150010, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100044, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA